Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

This activity was originally broadcast in conjunction with AMCP 2025.

Program Description

Endometrial cancer is the most common gynecologic malignancy in the US. While the majority of cases are diagnosed early and can be treated with surgery alone, for advanced or recurrent disease, the survival rate drops to below 20%. Immunotherapy-based regimens, such as immune checkpoint inhibitors, have shown promising results in improving survival and quality of life. While immunotherapy has shown significant promise, not all patients benefit, so identifying patients who are most likely to respond remains a challenge. This session will highlight best practices for appropriate use of immunotherapies in advanced endometrial cancer, outlining the utility of biomarker testing and translation to treatment selection. By developing protocols that advance precision medicine, ensure evidence-based sequencing of these therapies, and tailor treatment in gynecologic cancers, managed care and oncology pharmacists can play a crucial role in improving outcomes for patients. Strategies that incorporate immunotherapies into treatment plans and reduce inequities in medication access will also be discussed.

Target audience: Managed care pharmacists, oncology pharmacists

Type of activity: Application
Release date: April 8, 2025
Expiration date: April 8, 2026

Time to complete activity: 1.5 hours

Learner level: Foundational, Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Analyze the molecular pathways and genetic factors implicated in endometrial cancer to identify appropriate treatment strategies based on a patient's individual tumor profile.
• Interpret the most recent clinical data and evolving treatment guidelines for current and emerging immune-based therapies in the management of endometrial cancer to identify effective and appropriate treatment options for patients.
• Determine best practices for managed care in integrating the latest clinical evidence on immune-based therapies for endometrial cancer to ensure equitable access, appropriate utilization, and optimal patient outcomes.